1.Date of occurrence of the event:2022/01/21
2.Company name:PharmaEssentia Corp.
3.Relationship to the Company (please enter ��head office�� or
��subsidiaries��):Head office
4.Reciprocal shareholding ratios:N/A
5.Name of the reporting media:Global Arbitration Report and law360
6.Content of the report:AOP has asked a US court to grant discovery
of the Company to support criminal allegations.
7.Cause of occurrence:Clarification of reporting content
8.Countermeasures:
As reported by Global Arbitration Review and other media on January
21, 2022, the Company was subjected to an application by AOP Orphan
Pharmaceuticals (��AOP��) in the United States District Court for the
District of Massachusetts for an order to take discovery in aid of
a foreign criminal proceeding. The content is simply a unilateral and
frivolous accusation by AOP, which intends to disseminate to the media,
in the name of discovery, the defamation of the Company��s reputation.
Despite the fact that the dispute between the Company and AOP is a civil
and commercial dispute, AOP, in December 2020, still filed a criminal
accusation with the Frankfurt, Germany Prosecutor's Office, thereby
defaming and bringing shame on the Company��s image, in an attempt to
seriously damage the Company��s reputation. However, the Frankfurt
prosecutor has not agreed with such unfounded criminal complaint, and
has not conducted any further criminal investigation against the Company.
As such, this is just an indiscriminate action of AOP, attempting to
force the Company into compromise. The Company hereby solemnly clarifies
that the Company and its management team members have never committed any
criminal,illegal conduct, and after collecting evidence will take relevant
legal action against AOP.
9.Any other matters that need to be specified:
It takes a considerable time and expenses to develop a new drug.
In addition,the success of such development cannot be guaranteed.
Therefore, the investors will bear investment risk and should carefully
consider investment decisions.
Attachments
Original Link
Original Document
Permalink
Disclaimer
PharmaEssentia Corporation published this content on 22 January 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 22 January 2022 12:53:01 UTC.
PharmaEssentia Corp is a Taiwan-based company mainly engaged in the research, development, production and sale of new drugs. The Company is engaged in the research and development of new drugs, which are used for treatment of hematology, such as meloproliferative neoplasms (MPN), neutropenia, anemia; infectious disease, such as hepatitis C and hepatitis B; dermatology, such as psoriasis, and neurology, such as multiple sclerosis, among others. The Companyâs products include KX01, P1101, Polycythemia Vera (PV), PEG-GCSF, PEG-EPO and others. The Company distributes its products within domestic market and to overseas markets.
PHARMAESSENTIA CORPORATION 
